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Although a number of technical parameters are now
being examined to optimize microRNA profiling ex-
periments, it is unknown whether reagent or compo-
nent changes to the labeling step affect starting RNA
requirements or microarray performance. Human
brain/lung samples were each labeled in duplicate, at
1.0, 0.5, 0.2, and 0.1 g of total RNA, by means of two
kits that use the same labeling procedure but differ in
the reagent composition used to label microRNAs.
Statistical measures of reliability and validity were
used to evaluate microarray data. Cross-platform con-
firmation was accomplished using TaqMan microRNA
assays. Synthetic microRNA spike-in experiments
were also performed to establish the microarray sig-
nal dynamic range using the ligation-modified kit.
Technical replicate correlations of signal intensity
values were high using both kits, but improved with
the ligation-modified assay. The drop in detection call
sensitivity and miRNA gene list correlations, when
using reduced amounts of standard-labeled RNA, was
considerably improved with the ligation-modified kit.
Microarray signal dynamic range was found to be
linear across three orders of magnitude from 4.88 to
5000 attomoles. Thus, optimization of the microRNA
labeling reagent can result in at least a 10-fold de-
crease in microarray total RNA requirements with lit-
tle compromise to data quality. Clinical investigations
bottlenecked by the amount of starting material may
use a ligation mix modification strategy to reduce total
12RNA requirements. (J Mol Diagn 2012, 14:12–21; DOI:
10.1016/j.jmoldx.2011.08.005)
MicroRNA (miRNA) expression profiling platforms have
burgeoned in the last decade1–4 and promise to aid in
the diagnosis, prognosis, and therapeutic treatment of
human diseases such as cancer,5 cardiovascular dis-
ease,6 and diabetes.7 In response, intra-, inter-, and
cross-platform comparisons have recently emerged that
examine the use of microarray technology alone8,9 or in
contrast to other profiling methods.10–14 Such studies
have reported on the reliability and validity of widely used
miRNA discovery tools and to highlight the advantages
and limitations of these platforms.
However, there also remains a need to evaluate pre-
experimental factors, such as sample handling, process-
ing, storage, and nucleic acid quality, that may influence
miRNA expression profiling experiments.15 Whereas
three studies have demonstrated that miRNA detection
was possible in formalin-fixed paraffin-embedded (FFPE)
samples of up to 1016 or 1217 years old using extraction
kits from different manufacturers,18 stability and compa-
rability of miRNA expression signal using paired fresh-
frozen (FF) versus FFPE samples was reported in human
and murine specimens using different tissues ranging in
age from newly acquired19 to up to 3 years of age.17,20 In
contrast, when detecting the expression of longer RNA
transcripts, Abdueva et al21 found differences in paired
FF versus FFPE samples of up to 7.5 years of age, but
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ber of studies examined RNA extraction methods for
miRNA, with one that compared three isolation kits and
found general comparability among them,22 two that
used five kits and identified a preferred approach,23,24
and one that evaluated eight kits and found R2 correla-
tions exceeding 0.857 in all comparisons made.25 Con-
flicting reports have surfaced on the length of time RNA
can be stored after extraction for miRNA profiling, with
one study describing degradation after 3 days26 and
another demonstrating stability of up to 10 months,27
although cells from different species were used in each
study. Likewise, the quality of RNA28 has also been
called into question, with some showing that medium- to
high-integrity samples are required for reproducible
miRNA profiling using bovine29 and murine30 samples,
and another reporting negligible effects on highly de-
graded human samples.31 Consideration of these exper-
imental factors is crucial to ensuring valid and reliable
miRNA expression profiling results within and across
laboratories.
With the exception of next-generation sequencing
(NGS), all miRNA expression profiling approaches use a
labeling method to tag the target molecules of interest. In
the case of transcripts greater than 200 nucleotides in
length, the method used to amplify and/or label the mol-
ecules of interest before detection has been shown to be
important. Studies examining linear,32–36 exponential,37
and linear versus exponential38,39 amplification methods
revealed that although total RNA requirements can be
reduced significantly by using amplified RNA, quality
metrics such as comparability, sensitivity, and accuracy
were, in some cases, compromised when compared with
those using nonamplified RNA. However, these mea-
sures can be improved when robust data methods were
used.40 Next, evaluation of direct, indirect, and other
cDNA labeling approaches have shown that the method
chosen can reduce total RNA requirements, but that
gains in signal intensity values were also achieved along-
side, in some cases, a loss in labeling performance.41–46
Similar observations have been made when comparing
cRNA labeling methods.47–50 Even when performing rep-
licate experiments within51 or across52 laboratories, RNA
labeling has been shown to contribute to the variability
seen in gene expression outcome.
Although the body of work examining target labeling is
extensive, it is unclear whether and how these findings
can be applied to low abundance short transcripts 200
nucleotides. This is especially true in the case of miRNAs,
when considering that they represent only 0.5% to 9.2%
of total RNA in human and 0.1% to 1.3% in mouse and rat
tissue samples,53 but have also been shown to be pres-
ent, at some level, in a variety of human bodily fluids.54
Because many studies are limited in the amount of total
RNA available, such as those using tissues derived from
needle biopsies or laser capture microdissection, more
sensitive target labeling procedures are critical. Accord-
ingly, a growing number of amplification and labeling
strategies have been developed to aid in the detection of
these low-abundance RNAs.55 Although there are at least
two studies that have examined the effects of amplifica-tion on miRNA expression,10,56 there are currently no
studies that compare amplification or labeling effects
when direct labeling of mature miRNA is used. We there-
fore conducted a study to directly compare the Geni-
sphere FlashTag biotin-HSR (biotin-HSR) labeling kit to
the previously recommended FlashTag biotin-only (bio-
tin-only) assay (Genisphere, Hatfield, PA) for the Af-
fymetrix GeneChip miRNA Arrays. The biotin-HSR kit is a
modified version of the biotin-only assay. More specifi-
cally, a smaller more efficient labeling molecule, having a
higher number of biotins per unit mass of DNA, has been
used in the biotin-HSR kit compared to the DNA den-
drimer of the original FlashTag biotin kit. A total of 32
chips were used for this evaluation, followed by cross-
platform validation using TaqMan miRNA assays. In ad-
dition, the linear dynamic range of the GeneChip was
assessed using synthetic miRNA spiked-in at different
amounts, labeled with the biotin-HSR kit, on 12 chips. A
total of 44 microarray chips were used in this study.
Materials and Methods
Human Normal Tissue RNA
FirstChoice Total Brain (Lot#0906005) and Lung
(Lot#0904002) RNA samples were obtained from Am-
bion, Inc., certified to contain small RNAs, and quanti-
fied at 1 mg/ml (Applied Biosystems/Ambion, Foster
City, CA).
Labeling of RNA and Microarray Processing
Brain and lung total RNA samples were each labeled using
both the FlashTag biotin-only and FlashTag biotin-HSR RNA
labeling kits (Genisphere, Hatfield, PA) for the Affymetrix
GeneChip miRNA array. Each microarray contains se-
quences for 6703 miRNA probes, 499 small nucleolar RNA
(snoRNA), including 274 C/D and 127 H/ACA box RNA, 22
small cajal body–specific RNA (scaRNA), 10 5.8S ribo-
somal RNA, 162 Affymetrix controls, and 22 oligonucleotide
spike-in controls. Probes were developed by Affymetrix us-
ing the Sanger miRNA database v11 and contained addi-
tional snoRNAs and scaRNAs from the Ensembl database
and snoRNABase. RNA labeling was performed by the kit
manufacturer and efficiency assessed using an enzyme-
linked oligosorbent assay. Hybridization, washing, and
scanning of slides were performed according to the Af-
fymetrix and Genisphere protocols. Scanning was per-
formed using the miRNA-1_0 library file from Affymetrix for
the Flashtag biotin-only and miRNA-1_0_2Xgain for the
FlashTag biotin-HSR labeled samples. Refer to NCBI Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) study
GSE30045 to access Affymetrix CEL file data.
RNA Titration Experiments
Total RNA was prepared at recommended and reduced
input amounts from two different tissues to examine the
performance of the Affymetrix GeneChip miRNA array
and to evaluate the significance of using a new RNA
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ples were prepared containing 0.1 g, 0.2 g, 0.5 g,
and 1.0 g of total RNA. Two aliquots from each sample
were taken and labeled with either the biotin-only or bio-
tin-HSR kit. This process was carried out in duplicate for
each tissue. A total of 32 microarray chips were used for
this study.
Synthetic miRNA Spike-In Experiments
The mirVana miRNA Reference Panel v9.1 (Lot#072307)
was obtained from Ambion, Inc. and contains an equimo-
lar pool of 470 human, 224 murine, and 42 rat synthetic
miRNA oligonucleotides according to the Sanger miR-
Base sequence database, release 9.1 (Applied Biosys-
tems/Ambion, Foster City, CA).
Twofold serial dilution samples were then prepared
that contained from 5000 to 4.88 attomoles of miRNA (12
total, including a negative control). Synthetic miRNAs
were labeled using the FlashTag biotin-HSR RNA label-
ing kits. Hybridization, washing, and scanning of slides
were performed by Novartis according to Affymetrix and
Genisphere protocols. Scanning was performed using
the miRNA-1_0_2Xgain library file from Affymetrix.
Array Quality, Data Processing, and Detection
Calls
Raw intensity signal values of Affymetrix spike-in controls
indicated that array hybridization was successful (ie,
bioBbioCbioDCre). Likewise, raw intensity values
from an additional five Genisphere oligonucleotide spike-
ins control probes were all found to be 1000, used to
demonstrate poly(A) tailing and ligation (3 RNA oligos),
ligation (1 poly(A) RNA), and ligation and lack of RNases
in the RNA sample (1 poly(dA) DNA; data not shown).
Because labeling was an experimental factor being
tested, before analysis, raw signal intensity values were
Robust Multichip Average (RMA) background corrected,
quantile normalized, median polish summarized, and
log2 transformed separately for FlashTag biotin-only and
FlashTag biotin-HSR chip data.57–61 Processing was per-
formed using Partek Genomics Suite, version 6.5, build
6.10.0412 copyright 2010 (Partek, St. Louis, MO). Pres-
ent/absent detection calls for each probe, on every array,
were generated using the Affymetrix detection algorithm
and statistical significance testing implemented through
the miRNA QCTool, version 1.0.33.0. Details on how the
algorithm determines these calls are described in Appen-
dix A of the Affymetrix miRNA QC Tool User’s Guide 6
that, along with the software utility, are freely available on
the manufacturer’s website.
Reverse Transcription and Real-Time PCR
Total RNA was converted into cDNA and quantified using
individual Taqman assay kits for each miRNA of interest
(Applied Biosystems, Foster City, CA). Real-time PCR
followed the reverse transcription (RT) reaction, which
was modified to allow for the simultaneous synthesis ofcDNA by combining RT primers into pools A and B. The
multiplex RT protocol is a modification of the original kit
instructions and made available through the manufac-
turer by request.
RNU6B, SNORD44, and SNORD48 were selected as
candidate artificial normalization controls and previously
shown to be stable in a panel of 38 normal human tissues,
including Brain and Lung.62 Identification of hsa-let-7d
and hsa-miR-151-5p as candidate endogenous human
miRNA normalization controls, specific to the present ex-
periment, was performed, using microarray data, in the
following way: i) A signal detection call of “present” in
both Brain and Lung tissue across all input RNA titrations
and replicates using both the old and new labeling meth-
ods (79 of 847 miRNA probesets remained); ii) the ab-
sence of a statistically significant fold change difference
between brain and lung tissue (20 of 79 remained);
iii) removal of half the probesets with the lowest mean
signal intensity values and those previously shown63 as
inadequate (eight of 20 remained); and iv) use of Norm-
Finder64 to rank (data not shown) and select the most
stable miRNAs (two of eight remained).
Subsequent analysis of all five candidate control Ct
values by geNorm65 identified the combination of no
more than two miRNAs, ie, hsa-miR-151-5p/SNORD44
and hsa-let-7d/SNORD44, as the most stably expressed
housekeeping miRNAs in pools A and B, respectively
(data not shown). The expression of miRNAs, relative to
selected controls, was determined using the 2(–Ct)
method,66 and as also described online in an Applied
Biosystems document titled “User Bulletin #2: ABI Prism
7700 Sequence Detection System.”
Data Analysis
The mean or median was used as a measure of central
tendency for all continuous numerical variables, depend-
ing on whether the values followed a normal Gaussian
probability distribution. Student’s t-test was used when
performing two-group comparisons using parametric
data. An F-test for equality of variance was performed
before significance testing. A Wilcoxon rank-sum test
was used when performing two-group comparisons us-
ing nonparametric data. For descriptive statistics, signif-
icance was indicated if P was 0.05. Coefficient of vari-
ation (CV) for replicate chips was calculated as the SD of
the processed signal intensity value over the mean for
miRNAs called as present. The Pearson product-moment
correlation coefficient (r) was used to measure the linear
relationship of signal intensity values between replicate
chips. Spearman’s rank correlation coefficient () was
used to evaluate intra- and cross-platform miRNA gene
list comparisons. Unlike r,  measures the relative rank of
a miRNA gene in list A against its relative rank in list B,
thereby minimizing the effects of outlier data. For both r
and , the null hypothesis of no relationship was indicated
if P was 0.05. Statistical significance for differential
miRNA gene expression was determined using a false
discovery rate (FDR) P value of 0.05, unless otherwise
noted. Data analysis was performed using either Partek
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Institute, Cary, NC).
Results
Reliability (RNA Titrations)
Qualitative and quantitative measures of random error
within and between labeling kits were examined at all
input amounts of total RNA from both brain and lung
tissue. The number of present and absent detection calls
was first calculated for all replicate chips (see Supple-
mental Figure S1 at http://jmd.amjpathol.org). Percent
concordant (present and absent) calls for all probes on
the array using total RNA labeled with the biotin-only kit
was found to range from a grand mean of 95.0% for brain
to 95.8% for lung. Those values increased to 96.6% and
97.4%, respectively, when the RNA was labeled using the
biotin-HSR kit, although this was not a statistically signif-
icant finding (P  0.05 for both comparisons made). On
restricted examination of only the 847 human miRNA
gene probes, a statistically significant increase in the
number of detection calls was seen when concurrently
examining the differences in labeling kits alongside the
amount of input RNA used for microarray hybridization
(Figure 1). For brain samples, as the amount of biotin-only
labeled RNA is reduced from 1.0 g to 0.1 g, the mean
percentage of detected overlapping probes was de-
creased by 31%. However, this was statistically signifi-
cantly improved to a mean value of only 7% when using
biotin-HSR labeled RNA (P  0.0490). Likewise, for lung
samples, the loss was statistically significantly improved
from a mean value of 25% to 5% (P  0.04).
Irrespective of detection call, the reproducibility of pro-
cessed signal intensity values between duplicate chips
was next examined (Table 1). A statistically significant
improvement in the mean Pearson’s correlation coeffi-
cient value was observed for duplicate chips labeled
using the biotin-HSR kit. This finding was true for RNA
isolated from either brain or lung tissue (P  0.0001 for
both comparisons made). Individual correlations are pro-
vided in a 16  16 correlation matrix table for both brain
and lung samples (see Supplemental Tables S1 and S2
at http://jmd.amjpathol.org).
Finally, the CVs of the processed signal intensity val-
ues were calculated for all study samples (Figure 2).
There was a statistically significant reduction in the grand
median CV value for brain samples labeled with the bio-
tin-HSR versus biotin-only kit (2.59% to 1.25%; Wilcoxon
rank-sum P  0.05). However, a statistically significant
reduction in the grand median CV value for lung samples
was not observed (1.96% to 1.16%; Wilcoxon rank-sum
P  0.05).
Validity (RNA Titrations and RT Real-Time PCR)
Systematic error was evaluated by examining the inter-
platform agreement and cross-platform concordance of
brain to lung expression ratios for selected human
miRNAs. First, using differential miRNA gene expression
analysis, the numerical rank of all probes from the 1.0 gbiotin-only labeled RNA list was compared to the order
from lists using reduced amounts of input RNA (Table 2).
This process was repeated following sequential applica-
tion of filters, defined in Table 2, to the 1.0 g biotin-only
miRNA gene list to selectively reduce the number of
Figure 1. Comparison of detected miRNA genes. Probes for all 847 human
miRNAs were examined in (A) brain and (B) lung samples. The number of
present calls is indicated by the y axis. Comparisons on the x axis were done
to determine the number of overlapping present calls on chips containing 1.0
g of input RNA vs. 0.5, 0.2, and 0.1 g of starting material. One vs. 1.0 g
indicates the maximum possible overlap. Evaluations using the biotin-only
kit are represented by filled circles, biotin-HSR by filled squares, and biotin-
only versus biotin-HSR by open triangles. Statistical significance of *P 0.05.
Table 1. Correlation of Replicate Chip Signal Intensity Values
Tissue
Pearson product-moment correlation
(r)
P value
Labeling kit
Biotin-only global
Mean (1 SD)
Biotin-HSR global
Mean (1 SD)
Brain 0.955 (0.023) 0.978 (0.010) 0.0001
Lung 0.976 (0.011) 0.985 (0.006) 0.0001
The processed signal intensity value for each probe on a chip was
correlated with the corresponding probe on a replicate array (7819
probes total). Individual correlations between replicate arrays also were
all found to be statistically significant (P  0.0001; see Supplemental
Tables S1 and S2 at http://jmd.amjpathol.org). Global mean calculations
did not include correlations of a chip with itself, ie, where r  1.
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filters used, as the amount of biotin-only labeled RNA is
reduced, correlations with the 1.0 g biotin-only miRNA
gene list also falls. However, when using reduced
amounts of biotin-HSR labeled RNA, gene list correla-
tions remain steady. Depending on the miRNA gene list
filter used, there is a 60% to 93% reduction in the varia-
tion of correlation values when using reduced amounts of
biotin-HSR versus biotin-only labeled RNA.
Second, differentially expressed miRNA gene lists were
also generated for biotin-HSR labeled samples at each input
RNA amount and evaluated for overlap in statistically signifi-
cant transcripts (Figure 3). Of the 1779 human probes, a total
of 474 differentially expressed miRNA genes were identified.
As the amount of input RNA increases, the percentage of
miRNA genes unique to each list also increases from 4.3% for
Figure 2. Coefficient of variation within and between RNA labeling kits. The
percent CV was averaged for replicate chips at each input RNA amount
(0.1–1.0 g) within and between labeling kits for both brain and lung
samples. The interquartile range of the processed signal intensity value is
represented by shaded boxes, median value by a black line within a box, the
5th and 95th percentiles by the whiskers outside of each box and the number
of detected miRNA genes by filled boxes. CVs were calculated only for
miRNA genes called as present.
Table 2. miRNA Gene List Agreement within and Between RNA
Gene list filters applied*
(number of probes) 0 (n  7819) 1 (n
Biotin-only kit
0.5 g 0.765
0.2 g 0.693
0.1 g 0.588
Range (Max–Min) 0.177
Biotin-HSR kit
0.5 g 0.791
0.2 g 0.766
0.1 g 0.721
Range (Max–Min) 0.070
% Reduction in range using
Biotin-HSR kit
60 6
The brain versus lung differentially expressed miRNA gene list, derived
with lists generated using reduced amounts of starting material. The use
and is thus defined as the standard.
*Filters to the 1.0 g biotin-only miRNA gene list included the followin
probe must be present in at least one tissue; 3  filter 2  absolute fold chang
were statistically significant (P  0.0001; data not shown).0.1 g and 4.1% for 0.2 g to 8.8% for 0.5 g and 16.9% for
1.0g. The percentage ofmiRNAgenes that were detected in
more than 1 list, but not by all, is 22.8% for 0.1 g, 34.4% for
0.2 g, 55.6% for 0.5 g, and 68.0% for 1.0 g. There were
134miRNAgenes robustly detectedbyall listswith aminimum
absolute fold change of at least 10 or more for 86 genes, and
two to 10 for the remaining 48 genes.
Next, we took the 272 miRNA genes, from Table 2, and
compared it with the 474 identified miRNA genes from
Figure 3, to determine the gene list effects of using a new
labeling kit (see Supplemental Table S3 at http://jmd.
amjpathol.org). Of the 272 miRNA genes identified using
1.0 g of biotin-only labeled RNA, 136 of them were also
g Kits
9) 2 (n  601) 3 (n  422) 4 (n  272)
rman Rank Correlation Coefficient
0.961 0.972 0.978
0.915 0.938 0.949
0.830 0.879 0.903
0.131 0.093 0.075
0.962 0.968 0.973
0.957 0.970 0.977
0.937 0.960 0.972
0.025 0.010 0.005
81 89 93
g of biotin-only labeled RNA, was used in all pairwise correlations made
st 1.0 g of biotin-only labeled total RNA is required by the manufacturer
none, ie, all probes on the array; 1  human probes only; 2  filter 1 
Figure 3. Evaluation of statistically significant, differentially expressed
miRNA genes using Biotin-HSR labeled RNA. Genes were included in this
analysis using only human miRNA probes detected as present in at least brain
or lung tissue, with absolute fold change 1.5, and an FDR p 0.05. A total
of 419, 376, 218, and 184 differentially expressed miRNA genes were iden-
tified when using 1.0 g, 0.5 g, 0.2 g, and 0.1 g of input RNA,
respectively.Labelin
 177
Spea
0.734
0.662
0.558
0.176
0.762
0.733
0.692
0.070
0
from1.0
of at lea
g: 0 
e 1.5; and 4  filter 3  false discovery rate P  0.05. All correlations
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JMD January 2012, Vol. 14, No. 1Figure 4. Correlation of microarray data using TaqMan MicroRNA assays. Selection of human miRNAs based on statistically significant differential expression
1) in the brain (one high, two lows) and lung (one high, one low), and 2) found exclusively using either Biotin-HSR labeled RNA (one high, one low) or
Biotin-Only labeled RNA (two lows). Two additional miRNAs that were not statistically significant by either labeling method (one high, one low), and one low
detected using Biotin-only labeled RNA, were found to be undetectable by TaqMan Assay and therefore excluded. Eight miRNAs were used to generate these
graphs. Correlations were made using both Biotin-Only (left column) and Biotin-HSR (right column) labeled RNA. Fold change values and names of each
miRNA can be found in Supplemental Table S3 (available at http://jmd.amjpathol.org). Linear regression line determined using least-squares method.
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all, biotin-HSR miRNA gene lists; 122 were common to all
biotin-HSR miRNA gene lists; and 14 were unique to the
biotin-only miRNA gene list.
To further investigate the differences in these miRNA
gene lists, a cross-platform analysis was undertaken
comparing microarray results to TaqMan MiRNA assays
for 11 selected human miRNAs (Figure 4). Brain-to-lung
expression ratios derived from microarrays using the bi-
otin-HSR kit better correlated with TaqMan assay results
than did data from chips using biotin-only labeled RNA.
Pearson’s correlation coefficient improved from 0.915 to
0.986 for 0.1 g, 0.964 to 0.995 for 0.2 g, 0.975 to 0.994
for 0.5 g, and 0.994 to 0.996 for 1.0 g samples. The
use of expression ratios to correlate microarray with
TaqMan data has been previously demonstrated.67
Linear Dynamic Range (Synthetic miRNA
Spike-In Experiments)
To ensure that the use of the biotin-HSR labeling kit did
not adversely affect the linearity of the signal intensity
values, the concentration range in which valid brain and
lung sample measurements can be made was examined
by using spike-in synthetic miRNAs at increasing
equimolar amounts (Figure 5). The change in amount of
spike-in used on the array varied by three orders of
magnitude from a low of 4.88 to a high of 5000 attomoles
(0-attomole sample used as control). The change in sig-
nal intensity values across this range was found to be
linear for human (r  0.991), mouse (r  0.989), and rat
(r  0.987) synthetic spike-in miRNAs. Signal intensity
values from brain and lung samples of the same probes
used to detect the synthetic human miRNAs were also
plotted on the same graph and shown to fall within the
linear dynamic range tested.
Discussion
Previous studies in the mRNA literature have shown that
when laboratories are left to use their own labeling pro-
tocols, the comparability of microarray data within and
across centers is fair to low,68 but can be improved when
standardizing technical, experimental, and analytical fac-
tors.67 This is the first study to examine the issue in small
noncoding RNAs. Here, we analyzed miRNA expression
in human brain and lung samples and evaluated the
linear dynamic range of the Affymetrix miRNA GeneChip.
Our objective was to determine the differences, using two
RNA labeling kits, in the reliability and validity of miRNA
expression profiling data using recommended and re-
duced amount of input RNA. With the exception of the
ligation mix, each of the two kits used contained identical
reagents.
Several improvements to the quality of data were seen
when different RNA labeling kits were used. First, a sta-
tistically significant increase in the mean correlation co-
efficient for technical replicates in the brain and lung
were seen when comparing samples labeled using the
biotin-HSR versus biotin-only kits (Table 1; see also Sup-plemental Tables S1 and S2 at http://jmd.amjpathol.org).
These values were consistent with other studies that ex-
amined miRNA replicate chip signal intensity correla-
tions.9,10,13 Second, improvements in the grand median
CV values between labeling kits for each tissue was also
observed (Figure 2). Although the reduction in CVs was
statistically significant only for brain samples, median CV
values never exceeded 4%, regardless of the amount of
input RNA or labeling kit used. This is in stark contrast to
data from Sato et al,9 who found median CVs across five
different miRNA microarrays, using two different tissues,
to range from 15% to 100%. Likewise, detection calls
were also improved by labeling of RNA with the biotin-
HSR kit (see Supplemental Figure S1 at http://jmd.
amjpathol.org). The fact that these improvements were
not statistically significant suggest that both kits per-
formed equally well, with values ranging from
93.3%98.4% concordant. This data were generally su-
perior to the numbers reported by Sato et al,9 as well as
the percentages in the MicroArray Quality Control proj-
ect,67 although that study examined protein coding gene
expression profiling. Taken together, this data shows that
both the biotin-only and biotin-HSR labeling approaches
are reliable, and that changes to the labeling reagent in
the biotin-HSR improves reproducibility of the data.
This is the first study to show that changes to the
miRNA labeling reagent allows a reduction in the amount
of starting material used. First, it was shown that the
number of present calls for human miRNA genes was
reduced by only a mean value of 7% and 5% for brain
and lung samples, respectively, when the amount of bi-
otin-HSR labeled RNA used was decreased by 10-fold
from 1.0 g to 0.1 g (Figure 1). However, the decline
was increased to a mean value of 31% and 25% respec-
tively, when using the biotin-only labeled RNA. This large
detection loss seen using biotin-only labeling was similar
Figure 5. Dynamic range of the miRNA GeneChip using biotin-HSR labeling
kit. An equimolar pool of synthetic human, mouse, and rat miRNA was labeled
using the Biotin-HSR kit and hybridized in amounts ranging from 4.88 to 5000
attomoles (0 datapoint not shown; 12 arrays total). Probes for 465 of 470 human,
223 of 224 mouse, and 42 of 42 rat synthetic miRNAs were detected in all
hybridizations (rat and mouse data not shown). Global mean ( SEM) repre-
sented by X and error bars, respectively. Linear regression line in black. Intensity
values from the same human probes detected in all brain or lung hybridizations
(0.1 to 1.0 g) were plotted as black squares or white triangles, respectively.
Brain and lung data plotted as grand mean ( grand SEM).
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requirements by 2.5-, 5-, and 25-fold and found a 14%,
14%, and 33% decrease, respectively, in expression de-
tection sensitivity.61 These data show that detection calls
using as little as 0.1 g of biotin-HSR labeled RNA were
comparable to those generated when using 1.0 g of
biotin-only labeled RNA. When considering that as much
as 5 g of total RNA were required to produce reliable
signatures,69 a reduction in the amount of input RNA is of
particular relevance, especially in cases in which nonre-
newable clinical specimens are used for miRNA microar-
ray profiling.
Next, differentially expressed miRNA gene lists, from
reduced input RNA amounts, were correlated with the
one derived using 1.0 g total RNA labeled with the
biotin-only kit, which was the standard recommended
amount by Affymetrix/Genisphere. We found that, in con-
trast to the miRNA gene list correlations using reduced
amounts of biotin-only labeled RNA, variation in miRNA
gene rankings were minimized when using reduced
amounts of biotin-HSR labeled RNA, suggesting that the
use of less starting material does not affect the order of
identified genes on a list (Table 2). Finally, when directly
comparing filtered miRNA gene lists, generated using
different amounts of biotin-HSR labeled RNA (Figure 3),
at least 80% of the genes from each list were differentially
co-detected in one or more samples of varying input RNA
amounts, indicating a high degree of overlap regardless
of the amount of starting material used.
A cross-platform validation was undertaken to ensure
the integrity of the microarray data. Although next gener-
ation sequencing technologies could have been used,11
we choose quantitative real-time PCR because it is widely
accepted as a gold standard for cross-platform compar-
ison1 and currently offers a time and cost savings over
other methods. Eleven human miRNAs were selected
based on statistically significant high/low differential ex-
pression values in both brain and lung samples, as well
as a small subset with no difference (Figure 4). Much like
the reports from some9,22,67 but not all11 investigators, we
found good correlation between TaqMan and microarray
data. Furthermore, the correlation values remained0.98
for all comparisons made using microarray values from
any of the RNA dilutions labeled using the biotin-HSR. In
contrast, although still high, the correlations fell to a min-
imal value of 0.915 when evaluating biotin-only labeled
RNA samples.
Subsequently, our spike-in experiments showed that
the dynamic range of the microarray remained linear for
equimolar increases in synthetic miRNAs that varied by
three orders of magnitude. Similar results were reported
by Wang and company, who demonstrated linearity over
two orders of magnitude using the Agilent microarray
platform.70 These experiments were performed to ensure
that the signal intensity values in our experiments did not
exceed the linearity limits of the microarray when using
the new RNA labeling kit.
Finally, after the conclusion of these experiments and
analysis, the GeneChip miRNA 2.0 array was released by
Affymetrix to expand on coverage of 131 organisms (vs.
71 on the original array) using Sanger miRNA databasev15 (vs. v11) and to add 2202 probesets unique to pre-
miRNA hairpins (vs. 0). Although it was not tested, as that
was not the primary objective of this study, the biotin-HSR
kit is not limited to the original chip type, as it is now the
recommended strategy to label RNA for the 2.0 array. It
should also be noted that, currently, this kit has been
optimized only for short RNAs such as miRNAs, and is not
developed for longer RNA transcripts.
Results from this study highlight RNA labeling as an
important factor that can be used as a means of reducing
input RNA requirements and improving data quality for
miRNA microarray expression profiling studies. Labeling
reagent modifications can result in time and cost savings,
by eliminating or minimizing the need for preamplification
strategies, and enables the profiling of clinical samples
with limited quantities of total RNA. The biotin-HSR label-
ing kit is reliable, is valid, benchmarks well with the cur-
rently accepted gold-standard quantitative real-time
PCR, and is an improvement over the previous genera-
tion of Genisphere miRNA labeling reagents.
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